Department of Radiation Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences, Peking Union Medical College,Beijing 100021,China (Xia WL,Dai JR,Wang LH); Department of Radiotherapy,Fudan University Shanghai Cancer Center,Shanghai 200032,China (Hu WG)
Abstract： Charged particle therapy offers a better effect and obvious dosimetric and biological advantages over conventional radiotherapy in tumor control. Charged particles form Bragg peak in the dose distribution in tissue, enable most of energy to be deposited in the target region, and thus enhance tumor control and reduce the damage to normal tissues surrounding the tumor. With the increasing demand for charged particle therapy and the advances in particle accelerator, particle therapy technology is developing rapidly. The core apparatus of particle therapy facility is particle accelerator, and the accelerator type, particle type, and implementation technique determine the performance and therapeutic effect of the facility. This article provides a detailed comparative analysis of various particle therapies. Statistical data show that proton therapy is dominant in particle therapy, and high construction difficulty, large facility size, and extremely high cost have limited the development of heavy ion therapy. Nowadays, there are still some technical problems regarding charged particle therapy, and more clinical trials are required.
[1] Thariat J,Hannoun-Levi JM,Myint AS,et al. Past,present,and future of radiotherapy for the benefit of patients[J].Nat Rev Clin Oncol,2013,10(1):52-60.DOI:10.1038/nrclinonc.2012.203 [2] Kamada T,Tsujii H,Blakely EA,et al. Carbon ion radiotherapy in Japan:an assessment of 20 years of clinical experience[J].The Lancet Oncol,2015,16(2):e93-e100.DOI:http://dx.doi.org/10.1016/S1470-2045(14)70412-7 [3] Schulz-Ertner D,Tsujii H.Particle radiation therapy using proton and heavier ion beams[J].J Clin Oncol,2007,25(8):953-964. DOI:10.1200/JCO.2006.09.7816 [4] Hu YM,Zhang H,Dai J.Radiation oncology physics[M].Beiijing:Atomic Energy Press,1999:144. [5] Suit H,DeLaney T,Goldberg S,et al. Proton vs. carbon ion beams in the definitive radiation treatment of cancer patients[J].Radiother Oncol,2010,95(1):3-22. DOI:http://dx.doi.org/10.1016/j.radonc.2010.01.015 [6] Taheri-Kadkhoda Z,Bjrk-Eriksson T,Nill S,et al. Intensity-modulated radiotherapy of nasopharyngeal carcinoma:a comparative treatment planning study of photons and protons[J].Radiat Oncol,2008,3(1):1. DOI:10.1186/1748-717X-3-4 [7] Chu W T, Staples J W, Ludewigt B A, et al. Performance specifications for proton medical facility[R]. Lawrence Berkeley Lab., CA (United States), 1993. DOI:10.2172/10163935 [8] Liu SY.Current situation and development of proton therapy equipment[J].Bas Clin Med,2005, 25(2):123-127. DOI:10.3969/j.issn.1001-6325.2005.02.005 [9] Flanz J B. Operation of a cyclotron based proton therapy facility[C]//Proceedings of the International Conference on Cyclotrons and Their Applications. 2004:3-5. [10] ProBeam Superconducting Cyclotron[DB/OL][2016-05-10]. https://www.varian.com/oncology/products/treatment-delivery/superconducting-cyclotron. [11] MEVION S250 PROTON THERAPY SYSTEM[DB/OL][2016-05-10]. http://www.mevion.com/products/mevion-s250-proton-therapy-system. [12] Bloch C, Hill P M, Chen K L, et al. Startup of the kling center for proton therapy[C]//McDaniel F D, Doyle B L, Glass G A, et al. AIP Conference Proceedings. AIP, 2013, 1525(1):314-318.DOI:http://dx.doi.org/10.1063/1.4802340 [13] Kleffner C, Ondreka D, Weinrich U. The Heidelberg Ion Therapy (HIT) accelerator coming into operation[C]//McDaniel F D, Doyle B L. AIP Conference Proceedings. AIP, 2009, 1099(1):426-428. DOI:http://dx.doi.org/10.1063/1.3120065 [14] 质子重离子设备及主要技术[DB/OL][2016-05-10]. http://www.sphic.org.cn. [15] Chu W, Combs S, DeLaney T, Gomez D, Hug E, Orecchia R, Tsuboi K, Tsujii H, Cho KH. Reported by Milby AB. Carbon vs. proton for innovative applications of particle beam therapy. The annual Particle Therapy Cooperative Group (PTCOG 51) meeting in NCC, Goyang and Seoul, South Korea, May 14–19, 2012. OncoLink at PTCOG 2012. https://www.oncolink.org/conferences/article.cfm?id=6696. Accessed on March 17, 2016. [16] Blom M, Glimelius B, Lorin S, et al. Development of a scanning system for proton therapy in Uppsala[C]//Proceedings of the 6th European Particle Accelerator Conference, Stockholm, Sweden. 1998:2450-2451. [17] Lomax A.TU-C-BRA-01:an overview of proton therapy[J].Med Phys,2007,34(6):2552-2552. DOI:10.1118/1.2761360. [18] Particle Therapy Centers[DB/OL][2016-05-10]. http://www.ptcog.ch. [19] Goitein M.Trials and tribulations in charged particle radiotherapy[J].Radiother Oncol,2010,95(1):23-31.DOI:https://doi.org/10.1016/j.radonc.2009.06.012. [20] Mori S,Wolfgang J,Lu H M,et al. Quantitative assessment of range fluctuations in charged particle lung irradiation[J].Int J Radiat Oncol Biol Phys,2008,70(1):253-261.DOI:http://dx.doi.org/10.1016/j.ijrobp.2007.08.049. [21] Urie M,Goitein M,Holley WR,et al. Degradation of the Bragg peak due to inhomogeneities[J].Phys Med Biol,1986,31(1):1. [22] Lomax AJ.Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1:the potential effects of calculational uncertainties[J].Phys Med Biol,2008,53(4):1027-1042. [23] Lomax AJ.Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2:the potential effects of inter-fraction and inter-field motions[J].Phys Med Biol,2008, 53(4):1043-1056.
2017, Vol. 26 
